biocryst is terminating bcx5191 program, page-10

Muzza,

IMO, Nabi is still a better choice than Biocryst.

Biocryst has got nothing left to contribute to Biota if taken as a merger target. Its NET cash position is near ZERO. Its programs were going busted one after one (HCV program copied from Biota's, Peramivir no better than placebo, ect), its also got a big payroll. Biota is not focusing on its NN HCV program, Not the one that has patent dispute with Biocryst?

Nabi, although PC brought back a crappy deal in terms of price paid for Nabi assets, at least has contributed $27M cash. Nabi also had a small payroll at the time of merger.


Just my toughts.